Last updated on April 2019

Study of Pharmacodynamics Pharmacokinetics Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis


Brief description of study

This study will investigate the safety and efficacy of VAY736 administered subcutaneously (s.c.) every 4 weeks for 48 weeks. Approximately, 84 subjects will be randomized in a 1:1 ratio on top of local standard of care (SOC), to receive VAY736 or placebo.

Clinical Study Identifier: NCT03287414

Find a site near you

Start Over

Novartis Investigative Site

Birmingham, AL United States
  Connect »

Novartis Investigative Site

Los Angeles, CA United States
  Connect »

Novartis Investigative Site

Chicago, IL United States
  Connect »

Novartis Investigative Site

Baltimore, MD United States
  Connect »

Novartis Investigative Site

Saint Louis, MO United States
  Connect »

Novartis Investigative Site

Lebanon, NH United States
  Connect »

Novartis Investigative Site

Pittsburgh, PA United States
  Connect »

Novartis Investigative Site

Nashville, TN United States
  Connect »

Novartis Investigative Site

Salt Lake City, UT United States
  Connect »

Novartis Investigative Site

Montpellier cedex 5, France
  Connect »

Novartis Investigative Site

Cambridge, United Kingdom
  Connect »

Novartis Investigative Site

High Heaton, United Kingdom
  Connect »

Novartis Investigative Site

Edinburgh, United Kingdom
  Connect »

Novartis Investigative Site

Nottingham, United Kingdom
  Connect »